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RESEARCH ARTICLE
Evaluation of human dermal fibroblasts directly reprogrammed
to adipocyte-like cells as a metabolic disease model
Jian-Hua Chen1,2, Kim Jee Goh1,2, Nuno Rocha1,2, Matthijs P. Groeneveld1,2, Marina Minic1,2,
Timothy G. Barrett3, David Savage1,2 and Robert K. Semple1,2,*
ABSTRACT
Adipose tissue is the primary tissue affected in most single gene
forms of severe insulin resistance, and growing evidence has
implicated it as a site at which many risk alleles for insulin
resistance identified in population-wide studies might exert
their effect. There is thus increasing need for human adipocyte
models in which to interrogate the function of known and emerging
genetic risk variants. However, primary adipocyte cultures, existing
immortalised cell lines and stem-cell based models all have
significant biological or practical limitations. In an attempt to
widen the repertoire of human cell models in which to study
adipocyte-autonomous effects of relevant human genetic
variants, we have undertaken direct reprogramming of skin
fibroblasts to adipocyte-like cells by employing an inducible
recombinant lentivirus overexpressing the master adipogenic
transcription factor PPARγ2. Doxycycline-driven expression of
PPARγ2 and adipogenic culture conditions converted dermal
fibroblasts into triglyceride-laden cells within days. The resulting
cells recapitulated most of the crucial aspects of adipocyte biology
in vivo, including the expression of mature adipocyte markers,
secreted high levels of the adipokine adiponectin, and underwent
lipolysis when treated with isoproterenol/3-isobutyl-1-methylxanthine
(IBMX). They did not, however, exhibit insulin-inducible glucose
uptake, and withdrawal of doxycycline produced rapid delipidation and
loss of adipogenicmarkers. This protocol was applied successfully to a
panel of skin cells from individuals with monogenic severe insulin
resistance; however, surprisingly, even cell lines harbouring mutations
causing severe, generalised lipodystrophy accumulated large
lipid droplets and induced adipocyte-specific genes. The direct
reprogramming protocol of human dermal fibroblasts to adipocyte-
like cells we established is simple, fast and efficient, and has the
potential to generate cells which can serve as a tool to address some,
though not all, aspects of adipocyte function in the presence of
endogenous disease-causing mutations.
KEY WORDS: Fibroblasts, Adipocytes, Lipodystrophy,
Reprogramming, Insulin resistance
INTRODUCTION
Adipose tissue is a crucial nexus in the regulation of intermediary
metabolism, orchestrating metabolic adaptation to widely
fluctuating nutritional demands. It serves not just as an insulin-
regulated energy buffer, storing energy-dense triglyceride in times
of plenty, and releasing it as free fatty acids and glycerol in times of
privation, but also engages in more complex crosstalk with
metabolically important organs such as liver, muscle and brain. It
achieves this through fluxes of other metabolites and of a wide
variety of established or putative ‘adipokine’ hormones, pre-
eminent among which are leptin and adiponectin (Rosen and
Spiegelman, 2014; Fasshauer and Blüher, 2015; Cohen and
Spiegelman, 2016). In keeping with this key role of adipose tissue
in metabolic homeostasis, anatomical deficiency or dysfunction of
adipose tissue is now known to be the primary abnormality in many
single gene forms of dyslipidaemic insulin resistance, and a major
contributor to insulin resistance inmore complex pleiotropic syndromes
(Garg, 2011; Robbins and Savage, 2015; Hussain and Garg, 2016).
Growing population-wide genetic evidence has also implicated adipose
dysfunction as themediator of the associations observed among a raft of
common genetic variants and insulin resistance (Yaghootkar et al.,
2014, 2016; Shungin et al., 2015; Kilpeläinen et al., 2016; Lotta et al.,
2017). These findings have created a growing need for readily available
and robust human adipocyte models in which the effects of natural
genetic variation can be studied.
Several murine preadipocyte cell lines, most prominently the
3T3-L1 line (Green and Meuth, 1974), have been heavily studied,
and have been the major tool in the delineation of the transcriptional
network underlying adipogenesis over the past three decades
(Rosen and MacDougald, 2006; Poulos et al., 2010). Some human
cell lines also exist, including hMADS cells, isolated from the
stromovascular fraction of infant adipose tissue (Rodriguez et al.,
2004; Bezaire et al., 2009), SGBS cells, cultured from an individual
with an overgrowth syndrome of undefined molecular aetiology
(Fischer-Posovszky et al., 2008), and ChubS7 cells, primary
preadipocytes immortalised with telomerase and HPV-E7
expression (Darimont et al., 2003); however, most are either too
fragile to permit genetic engineering and clonal selection while
retaining differentiation potential, or else recapitulate only poorly
key behaviours of bona fide adipocytes, including secretion
of leptin, insulin-stimulated glucose uptake and suppression of
lipolysis. Primary cells can be used, but establishing cultures
involves invasive biopsy procedures, which are impractical or
hazardous in those with lipodystrophy, and the resulting cells can
only be studied for relatively short periods before replicative
senescence and differentiation failure supervene.
A further option is to utilise stem cells, whether embryonic stem
cells (the use of which is practically constrained by licensing and
ethical considerations) or induced pluripotent stem cells (iPSCs).
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have been published (Ahfeldt et al., 2012; Noguchi et al., 2013; Lee
and Cowan, 2014; Mori et al., 2016; Guénantin et al., 2017);
however, although this approach can generate cells with close
transcriptional and functional similarities to primary adipocytes
(Ahfeldt et al., 2012), it is time consuming and relatively labour
intensive, taking several months to achieve, whether via
reprogramming of primary human cells or via CRISPR/Cas9-
mediated editing of an established iPSC line (Ahfeldt et al., 2012).
In addition, generation of disease-specific iPSCs is often
complicated by factors such as low efficiency of reprogramming,
variability in protocols and the high cost of cell culture. Moreover,
cellular changes during the reprogramming process, culture-
induced spontaneous differentiation and differences in genetic
background can constrain their use in cellular phenotyping of
disease (Soldner and Jaenisch, 2012). These disadvantages are
often prohibitive, rendering screening of numerous individuals
laborious and impractical.
A faster approach to utilising primary human cells is direct
reprogramming to the differentiated cell type of interest, thereby
bypassing the generation of true pluripotent cells as intermediates
(Vierbuchen and Wernig, 2011; Tanabe et al., 2015). This approach
generally exploits knowledge about transcriptional and hormonal
regulation of differentiation, and potentially offers the advantages of
fast dynamics and high efficiency, making relatively rapid screening
of numerous individuals feasible (Vierbuchen and Wernig, 2011).
The detailed knowledge of the stereotyped transcriptional network
driving adipogenesis that has accrued over the past 25 years, and
particularly the dominant role of peroxisome proliferator-activated
receptor gamma (PPARγ) as the master adipogenic transcription
factor (Rosen and MacDougald, 2006), means that direct
reprogramming of suitable cells to adipocytes is particularly
tractable. Moreover, scattered evidence suggests that fibroblasts
cultured from human dermis, obtainable by a quick and simply
biopsy procedure, include mesenchymal progenitor cells (Feisst
et al., 2014). We thus set out to assess whether readily cultured
human dermal fibroblasts could be driven directly to become
adipocytes as a cheaper and more convenient way of studying
human disease variants in a disease-relevant cell type.
RESULTS
Direct reprogramming of dermal fibroblasts into adipocyte-
like cells
We first constructed a recombinant lentivirus (pSLIK-PPARγ2)
incorporating the longer PPARγ2 splice variant of the PPARG gene,
which is highly expressed in adipose tissue (Tontonoz and
Spiegelman, 2008) (Fig. 1A). This vector permitted conditional
overexpression of PPARγ2 under the control of doxycycline via a
third-generation version of the reverse Tet transactivator (rtTA3),
which has been shown to have improved doxycycline sensitivity
and activity (Das et al., 2004; Markusic et al., 2005; Shin et al.,
2006). Western blot analysis showed that PPARγ2 overexpression
in pSLIK-PPARγ2-transduced cells was induced 1 day after
addition of doxycycline (1 µg/ml) and was maintained strongly in
the presence of doxycycline (Fig. 1B). PPARγ1 was also detected,
although at a much lower expression level (Fig. 1B); however, it was
not possible to discriminate whether this resulted from minor usage
of a second PPARG translational start codon in the transduced
cDNA, or upregulation of endogenous PPARγ1 by PPARγ2
overexpression. Both PPARγ2 and low level PPARγ1
overexpression were rapidly turned off by removing doxycycline
from the culture medium, becoming almost undetectable 1 day after
doxycycline withdrawal (Fig. 1B).
To determine whether pSLIK-PPARγ2-transduced dermal
fibroblasts can be directly reprogrammed into adipocyte-like cells,
we subjected the stable cell lines to doxycycline induction for 2 days,
followed by exposure to a standard adipogenic protocol. This
consisted of use of an adipogenic cocktail [1 µM insulin, 200 nM
rosiglitazone, 1 µM dexamethasone, 0.5 mM 3-isobutyl-1-
methylxanthine (IBMX)] for 2 days followed by insulin and
rosiglitazone at the same concentrations for 2 days, with
rosiglitazone only for the rest of the culture period (Fig. 1C).
Doxycycline was included throughout to maintain PPARγ2
overexpression. Morphological changes (loss of typical spindle-
shaped, bipolar and refractile characteristics to become rounder and
less refractile) were noticed as early as 1 day after adipogenic cocktail
addition and were accentuated on day 2, when the appearance of
small lipid droplets was noted. During the course of adipogenic
differentiation, lipid droplets continued to accumulate and merge,
with most lipid droplet-containing cells containing a dominant lipid
droplet surrounded by many small droplets. Nearly homogenous
differentiation and lipid accumulation were confirmed by Oil Red O
staining (Fig. 1D). Stable cell lines remained undifferentiated in the
absence of doxycycline, despite being subjected to the adipogenic
protocol (Fig. 1D). We observed that the majority of reprogrammed
cells which bear a prominent large lipid droplet were still alive at
day 70, when cultures were terminated (Fig. S1).
Quantitative real-time PCR revealed that reprogrammed lipid
droplet-containing cells expressed a panel of adipocyte marker
genes, including FABP4 (encoding aP2), ADIPOQ (encoding
adiponectin), CEBPA (encoding C/EBPα) and SLC2A4 (encoding
GLUT4) (Fig. 2A); however, LEP expression (encoding leptin) was
suppressed, even compared with the low baseline in skin cells
(Fig. S2A). Expression of brown adipocyte marker genes was variable,
with UCP1 strongly induced transcriptionally, but other genes showed
either no increase (DIO2 and CYC1) or only a moderate increase
(ELOVL3) (Fig. S3A). Expression of aP2, adiponectin and C/EBPα
was confirmed by western blot analysis (Fig. 2B); however, there was
no evidence of UCP1 protein expression (Fig. S3B). Western blot
analysis also revealed that insulin receptor and perilipin protein
expression were induced in reprogrammed ‘adipocyte-like’ cells
(Fig. 2B), while IGF1 receptor expression was markedly supressed up
to day 8, after which time it gradually returned to a level of expression
close to that of undifferentiated cells (Fig. 2B). GLUT4 protein
expression showed no significant change during the course of exposure
to adipogenic medium (Fig. 2B).
Secretion of adiponectin by reprogrammed adipocyte-like cells
was determined by dissociation-enhanced lanthanide fluorescent
immunoassay (DELFIA) in media exposed to cells for 48 h.
Adiponectin became detectable on day 4 and increased up to day 12,
after which time it decreased, in good agreement with western blot
analysis results (Fig. 2C). High sensitivity DELFIA showed leptin,
by contrast, to be suppressed from a low baseline level to be barely
detectable in adipocyte-like cells (Fig. S2B).
It is believed that once the adipogenic programme is initiated, a
cascade of pro-adipogenic factors is activated that eventually leads
to self-sustaining mutual upregulation of PPARγ2 and C/EBPα
(Rosen and MacDougald, 2006; Lefterova and Lazar, 2009). We
thus sought to determine whether the adipocyte-like phenotype was
maintained in the absence of exogenous PPARγ2 expression, as has
been reported in stem cell-derived adipocytes (Ahfeldt et al., 2012).
Withdrawal of doxycycline from adipocyte-like cells at 10 days of
differentiation led to abrupt cessation of PPARγ2 expression,
however, with attendant decreased expression of insulin receptor
(Fig. 2D) and delipidation of adipocyte-like cells (Fig. 2E).
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Insulin-stimulated glucose uptake into adipocytes accounts for
only a small proportion of insulin-stimulated glucose disposal
compared with skeletal muscle, the major site of insulin-stimulated,
GLUT4-mediated glucose disposal (Klip and Paquet, 1990).
Nevertheless, glucose uptake into adipose tissue is important for
de novo lipogenesis. Furthermore, as murine 3T3-L1 adipocytes in
culture show notably robust insulin-stimulated glucose uptake,
unlike primary muscle cells or muscle-derived cell lines, it has been
in adipocytes that many of the key studies of the biochemistry and
cell biology of insulin-stimulated glucose uptake have been
undertaken (Saltiel and Kahn, 2001). The degree of insulin
stimulated glucose uptake in human adipocyte cell lines is
generally much smaller than in 3T3-L1 adipocytes (commonly
less than twofold compared with five- to tenfold). Despite strong
upregulation of insulin receptor expression using the adipogenic
protocol in conjunction with PPARγ2 overexpression in this study,
we did not observe any insulin-stimulated glucose uptake in the
reprogrammed adipocyte-like cells (Fig. 2F).
Farmer and co-workers (El-Jack et al., 1999; Hamm et al., 1999)
previously reported that although PPARγ overexpression was
sufficient to drive both NIH-3T3 and Swiss-3T3 cells to assume
adipocyte-like morphology and express key adipocyte marker genes
such as Fabp4, insulin-dependent glucose uptake was seen only in
differentiated Swiss-3T3 cells. Lack of insulin-dependent glucose
uptake in differentiated NIH-3T3 cells was shown to result from
absence of C/EBPα and GLUT4 expression, as overexpression of
C/EBPα was sufficient to induce GLUT4 expression and insulin-
dependent glucose uptake in the resulting differentiated NIH-3T3
Fig. 1. Direct reprogramming of human
dermal fibroblasts into adipocyte-like
cells using inducible lentiviral PPARγ2
overexpression. (A) Schematic showing
predicted constitutive (black) and
doxycycline (DOX)-induced (orange)
transcripts from the pSLIK lentivirus.
(B) Western blot analysis of kinetics of
PPARγ2 overexpression in human dermal
fibroblasts transduced with pSLIK-
PPARγ2 recombinant lentivirus, which
were cultured in the presence of DOX
(1 µg/ml) followed by DOX withdrawal for
the indicated length of time. Equal loading
was revealed by anti-calnexin antibody.
(C) Schematic showing the direct
reprogramming protocol, which consists
of DOX induction for 2 days, followed by
2 days culture in the presence of
adipogenic cocktail and 2 days in the
presence of insulin and rosiglitazone, and
then rosiglitazone only for the rest of the
culture. (D) Oil Red O staining showing
the successful direct conversion of
human dermal fibroblasts into
triglyceride-laden adipocyte-like cells.
Scale bars: 200 µm. The high
magnification inset demonstrates a
representative adipocyte with a large
dominant lipid droplet.
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cells. We therefore assessed the effect of combining adipogenic
induction of skin cells with overexpression of C/EBPα either alone
or in combination with PPARγ2 (Fig. S4A). We observed that
conversion into adipocyte-like cells by C/EBPα overexpression
alone was inefficient, and that the resulting adipocyte-like cells
generally accumulated small lipid droplets with no dominant
droplet as seen in adipocyte-like cells by PPARγ2 overexpression
(Fig. S4B). Moreover, immunoblotting revealed that neither C/EBPα
alone nor C/EBPα with PPARγ2 (Fig. S4C) enhanced GLUT4
expression in the reprogrammed cells (Fig. S4D).
A further characteristic feature of mature white adipocytes is the
ability to undergo lipolysis with release of glycerol upon stimulation
Fig. 2. Characterisation of direct reprogrammed adipocyte-like cells. (A) Quantitative RT-PCR analysis of expression of marker genes of white adipocytes
(FABP4, ADIPOQ, CEBPA and SLC2A4) at four different differentiation time points. (B) Western blot analysis of key proteins in adipocyte-like cells during
direct reprogramming up to day 18, using antibodies as indicated. (C) Adiponectin secretion from direct reprogrammed adipocyte-like cells in 48-h culture medium
was determined with DELFIA. (D) Downregulation of PPARγ2 and then INSR expression after removal of DOX from the culture medium. (E) Delipidation
was also observed in reprogrammed adipocyte-like cells. Images were taken 10 days after DOX withdrawal (left) or with DOX included in the culture medium
throughout (right). Scale bars: 100 µm. (F) Glucose uptake assay. (G) Lipolysis assay of direct reprogrammed adipocyte-like cells treated with isoprotenerol
and/or IBMX. Data are mean±s.e.m. from three independent experiments (***P<0.001, Student’s t-test).
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of certain adrenergic receptors (predominantly β3 in mice and α2 in
humans) (Wang et al., 2008). Lipolysis assays demonstrated that
the reprogrammed adipocyte-like cells were capable of undergoing
lipolysis when exposed either to the adrenergic agonist
isoproterenol or the phosphodiesterase inhibitor IBMX. No
synergy was observed between treatments (Fig. 2G).
Comparison with stem cell-derived human adipocytes
Having demonstrated that adipocyte-like cells derived directly from
dermal fibroblasts exhibit some but not all characteristics of
adipocytes, we sought to compare them to adipocytes derived from
human embryonic stem cells using a protocol closely similar to that
previously described (Fig. S5A). Stem cells were first differentiated
to mesenchymal stem cells before acute infection with the same
conditional PPARγ2-expressing lentivirus as used in dermal
fibroblasts. Adipogenic differentiation was then undertaken in the
presence of doxycycline for 16 or 21 days. Like the dermal fibroblast-
derived cells, the embryonic stem cell-derived cells accumulated
neutral lipids (Fig. S5B), strongly induced a panel of adipocyte-
specific genes at mRNA level (Fig. S6A), as well as adiponectin
secretion (Fig. S6B), and exhibited isoproterenol-stimulatable
lipolysis (Fig. S6C). Also, like dermal fibroblast-derived adipocyte-
like cells, these cells did not upregulate leptin expression, and
although they did exhibit significant upregulation of glucose uptake
on insulin stimulation, the increase was modest, at only 1.7-fold
(Fig. S6D). Contrary to previous findings, neither the expression of
mature adipocyte genes nor the expression of endogenous PPARγ
expression were robustly maintained after 1 week of doxycycline
deprivation, with gene expression of all markers falling sharply in all
cell lines tested (Fig. S7). Cellular lipid droplets were preserved after
1 week of doxycycline deprivation, however (Fig. S8), unlike in
dermal fibroblast-derived adipocyte-like cells.
Reprogramming of dermal fibroblasts derived from patients
with genetic diseases
We next sought to determine whether the direct reprogramming
approach could be applied to human cells harbouring known
mutations associated with Mendelian forms of severe insulin
resistance, and whether disease-relevant phenotypic abnormalities
could be observed in the resulting adipocyte-like cells. The genetic
defects studied, and the clinical phenotypes of the donors, which
included varying degrees of lipodystrophy in many cases, are
summarised in Table S1. We found that cell lines harbouring
pathogenic mutations in PPARG, INSR, LMNA, BSCL2, PIK3R1,
WRN, BLM, NSMCE2 ALMS1 or PCYT1A all exhibited lipid
accumulation upon PPARγ2 overexpression and culture in
adipogenic conditions (Fig. 3; Figs S9 and S10), despite many of
these Mendelian disorders featuring some degree of failure of
adipose tissue accumulation, ranging from generalised moderate
paucity in the case of insulin receptoropathy, through partial
lipodystrophy in the case of PPARG and LMNA, to severe
generalised lipodystrophy in the case of BSCL2. Indeed, despite
the severity of the lipodystrophy associated with biallelic BSCL2
mutations, lipid droplets were indistinguishable in size and
morphology from those in wild-type cells treated the same way
(compare Fig. 3A and Fig. 1D). Adipocyte marker gene and protein
expression (FABP4, ADIPOQ and CEBPA) were also strongly
induced in all cells assessed (Fig. 3B,C), with the exception of
FABP4 in LMNA mutant cells. Adiponectin secretion was also
detected by DELFIA in culture media (Fig. 3D). Induction of
insulin receptor and suppression of IGF1 receptor expression, as
seen before, were observed in patient cell lines, with the exception
of the line harbouring biallelic INSR mutations, in keeping with the
known effects of these INSR mutations to reduce protein expression
of the receptor (Fig. 3C). Expression of the pathogenic p.Arg482Trp
LMNAvariant was shown in the relevant cell line using a mutation-
specific antibody (Fig. 3C), while cDNA sequencing confirmed
expression of the PPARG and BSCL2 variants studied (Fig. 3E).
Notably, however, expression of the PPARG mutant was no longer
detectable after doxycycline addition, consistent with a high level of
overexpression of wild-type protein. Reprogrammed fibroblasts
from a patient with Alström syndrome and biallelic ALMS1
mutations also displayed absent ALMS1 immunostaining at the
centrosome (Fig. S9).
DISCUSSION
Study of monogenic human disorders has unequivocally established
impaired adipose tissue development or adipose dysfunction to
be sufficient to produce severely insulin resistant diabetes,
dyslipidaemia, fatty liver and ovulatory dysfunction (Semple
et al., 2011). Emerging evidence suggests moreover that a subset
of common human genetic variants confer genetic susceptibility to
prevalent metabolic syndrome through a similar ‘lipodystrophic’
mechanism (Yaghootkar et al., 2014, 2016; Shungin et al., 2015;
Kilpeläinen et al., 2016; Lotta et al., 2017). To pursue this notion
mechanistically, and to test a growing repertoire of candidate
‘lipodystrophy’ susceptibility genes, requires study of gene variants
in a relevant adipocyte or preadipocyte context, ideally with
preservation of gene dosage and genomic context, and in a system
that is scalable, to permit interrogation of multiple variants.
Primary preadipocytes, or adipose-derived stromal vascular cells,
are obtained by invasive tissue biopsy, show variable but often low
differentiation efficiency and can only be studied for a short period
in culture. Mesenchymal stromal cells from bone marrow or other
sources can also be differentiated into adipocytes, but similarly have
limited proliferative and differentiation capacity (Mauney et al.,
2007). Early attempts to generate adipocytes by differentiation of
pluripotent human embryonic stem cells and iPSCs were also
inefficient (Taura et al., 2009), but this approach was refined more
recently by using conditional overexpression of PPARγ2 in
conjunction with chemical induction of differentiation of iPSC-
derived mesenchymal progenitor cells, yielding ∼90% of cells with
white adipocyte characteristics (Ahfeldt et al., 2012). These cells
were reported to show stable adipocyte-like characteristics even
after turning off PPARγ2 transgene expression, and, moreover,
exhibited insulin-stimulated glucose uptake and inducible lipolysis
among other characteristics of mature adipocytes. Other reports
have shown subsequently that adipocytes derived from iPSCs or
embryonic stem cells can maintain adipocyte characteristics for
4 weeks after transplantation into mice (Noguchi et al., 2013), with
one protocol reporting development in vivo of well vascularised
beige-like adipose tissue, capable of beta-adrenergic-responsive
glucose uptake (Guénantin et al., 2017). Nevertheless, these
protocols are labour- and cost-intensive, prohibiting ready scaling
for study of a wide range of mutations.
Direct reprogramming of somatic cells into other differentiated
lineages has been achieved without an intermediate pluripotent stage
for several cell types, in general relying on overexpression of key
transcription factors previously established to be pivotal for
development of the destination cells in question. Indeed, conversion
of human dermal fibroblasts into haematopoietic progenitors
(Szabo et al., 2010), various neurones (Caiazzo et al., 2011),
cardiomyocytes (Nam et al., 2013), osteoblasts (Yamamoto et al.,
2015), endothelial progenitor cells (Van Pham et al., 2016) and
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Schwann Cells (Sowa et al., 2017) has previously been described.
The power of PPARγ2 as the ‘master regulator’ of adipogenic
differentiation (Tontonoz and Spiegelman, 2008; Lefterova et al.,
2014) makes this approach potentially appealing for adipocytes
also, as illustrated by early studies in which its overexpression
was used to turn mouse embryonic fibroblasts into adipocytes
(Tontonoz et al., 1994).
We demonstrate that conditional expression of PPARγ2 in
lentivirally transduced cells combined with a conventional
adipogenic induction cocktail swiftly induced accumulation of
large lipid droplets, as well as inducing expression of a panel
of white, but not brown, adipocyte-specific genes, and high levels of
adiponectin secretion. Another change in gene expression relevant
to metabolic disease modelling was a marked increase in insulin
Fig. 3. Direct reprogramming of dermal fibroblasts derived from patients with metabolic diseases caused by mutations on PPARγ, insulin receptor,
lamin and BSCL2. (A) Oil Red O staining showing that the four patient cell lines (SIR1-SIR4) were all successfully converted into adipocyte-like cells using
our direct reprogramming protocol, as schematised in Fig. 1. Scale bars: 200 µm. (B) Quantitative RT-PCR analysis of the expression of white adipocyte
marker genes. (C) Western blot analysis of key proteins in undifferentiated control cells (DOX−) and reprogrammed adipocyte-like cells (DOX+). Sequencing
confirmation of mutations onPPARG andBSCL2 genes is shown for SIR1 andSIR4, respectively. (D) Adiponectin secretion from direct reprogrammedadipocyte-
like cells in 48-h culture medium was determined with DELFIA. Data are mean±s.e.m. from three independent experiments (***P<0.001, Student’s t-test).
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receptor protein expression with concomitant downregulation of
IGF1 receptor expression. Reprogrammed cells also exhibited
isoproterenol or IBMX-stimulated lipolysis, in keeping with
functional properties of mature white adipocytes.
Despite recapitulating some key aspects of adipocyte
morphology, gene expression and function, however, the
reprogrammed cells failed to recapitulate some important
adipocyte behaviours relevant to at least some disease
modelling. Thus, no insulin-stimulated increase in glucose
uptake was seen in the adipocyte-like cells despite high levels
of insulin receptor expression. Consistent with this, induction of
GLUT4 protein expression was weak whether or not C/EBPα,
which was previously suggested to induce GLUT4 expression
(Hamm et al., 1999), was also overexpressed. The reprogrammed
cells in this study also failed to induce leptin expression or
secretion compared with nonreprogrammed dermal fibroblasts.
Although PPARγ and CEBPα have been said to form a self-
sustaining expression positive-feedback loop, we moreover
found that the adipocyte-like phenotype of ‘reprogrammed’
fibroblasts was reversible when doxycycline-driven PPARγ2
expression was turned off, with rapid delipidation and loss of
adipocyte gene expression, including endogenous PPARG, and
of adiponectin secretion seen over the course of 1 week. For all
the central importance of PPARG in the transcriptional control of
adipogenesis, normal adipogenesis involves a complex cascade
of activation of transcriptional networks as well as extensive
chromatin remodelling (Siersbæk et al., 2012; Lefterova et al.,
2014), and it is presumably the lack of such wider remodelling
that determines the dependence of the adipocyte-like phenotype
we report on continued artificial overexpression of PPARG. It
will be of great interest to extend development of the model we
describe to explore whether co-expression of other adipogenic
factors can further enhance its robustness and fidelity in
replicating mature adipocyte properties. One transcription
factor of particular interest is ZFP423, which several studies
have strongly implicated in priming perivascular cells for
adipogenic differentiation (Gupta et al., 2012).
Collectively these findings raise the question as towhether the cells
generated by the protocol described are truly ‘adipocytes’ or rather are
simply cells with forced overexpression of PPARG-responsive genes,
including those required for development of lipid droplets and
adiponectin, which are known to be upregulated, and suppression of
genes such as LEP, encoding leptin, which is known to be regulated
negatively by PPARG (Hammarstedt et al., 2005). The latter
possibility would still lend the cells utility for the study of certain
aspects of adipocyte function, and indeed although the cells have
shortcomings as bona fide adipocyte models, some of these are
shared by other existing human adipocyte models. Although iPSC-
derived cells have been reported to show insulin-stimulated glucose
uptake (Ahfeldt et al., 2012), and although we replicated this finding,
the degree of stimulation, as for other human adipocyte cell lines, was
very small, such that the dynamic range of the response is unlikely to
be of great use in assessing perturbations that induce insulin
resistance. Furthermore, while leptin was reported to be expressed
in iPSC-derived adipocytes, levels of protein secretion were
extremely low (Ahfeldt et al., 2012). Finally, in our hands, even
iPSC-derived adipocytes, although derived using a protocol very
closely mimicking the prior study, showed marked loss of adipocyte
gene expression, including endogenous PPARγ, after withdrawal of
doxycycline-driven PPARG2 expression. These findings suggest that
the advantages of using an iPSC-based approach to study human
mutations in the correct genomic context are marginal only, at least
when limited to studies in cell culture, and are substantially offset by
the prolonged and expensive nature of the protocol.
We applied our reprogramming protocol to a panel of cells
derived from patients with monogenic insulin resistance either
attributable to an insulin signalling defect (INSR, PIK3R1), to
primary lipodystrophy (BSCL2, PCYT1A, PPARG or LMNA), or
forming part of a more complex, pleiotropic syndrome (ALMS1,
WRN, BLM, NSMCE2). All cells could be transformed into lipid-
laden, adipocyte-like cells, and while some variation in the
efficiency of this process was observed across the panel of cells
studied, similar variation was seen in wild-type cells, and is thus
most likely attributable to intrinsic differences in cell proliferation
and differentiation potential related to donor age or other factors not
specific to the mutation harboured. The pathogenic genetic
perturbation could be detected in four of the five cell lines in
which it was assessed, whether this was loss of protein expression
(compound heterozygous INSR or ALMS1mutations), expression of
mutated protein (LMNA p.Arg482Trp heterozygosity) or
expression of mutant mRNA (BSCL2). The only exception was
cells with a pathogenic PPARG mutation, which could be detected
in cDNA at baseline but not after PPARG2 overexpression, which
presumably swamped the endogenous mutant expression.
Surprisingly, no overt defects in lipid droplet accumulation was
seen for any genotype, even where the corresponding human
disorder features near complete absence of adipose tissue, as in
generalised lipodystrophy caused by BSCL2 mutations. The
underlying mechanisms remain the subject of research, but
several studies have invoked a crucial role for BSCL2 in lipid
droplet formation or function (Payne et al., 2008; Robbins and
Savage, 2015). Although an obligate role for BSCL2 in lipid droplet
biogenesis would appear at odds with the observations in this study,
lipid droplets can occur in some cellular contexts even in BSCL2-
related lipodystrophy, such as in severely fatty liver cells. A
previous study of adipogenesis of iPSC-derived human cells from a
patient with BSCL2 mutations did show impaired adipose
differentiation (Mori et al., 2016), while other studies have
suggested that the defect in adipose differentiation of cells with
knockout or knockdown of BSCL2/Bscl2 can be partially overcome
to some extent by activation of PPARG (Chen et al., 2009; Prieur
et al., 2013). Our findings confirm that the BSCL2 gene is
dispensable for lipid droplet formation in the context of forced
PPARG overexpression and application of an adipogenic protocol,
but caution that some cell autonomous defects relevant to the in vivo
human phenotype can be masked by the strength of PPARG
activation employed in this model. For most of the other cell lines
studied, the associated adipose phenotype is more complex, variable
or age dependent, and calibration or adaptation of the
reprogramming protocol might further enhance the value of the
model in probing cell autonomous disease mechanisms.
In conclusion, we describe a protocol involving conditional
PPARγ2 overexpression and a chemical adipogenic cocktail to turn
dermal fibroblasts into lipid-laden adipocyte-like cells. These
adipocyte-like cells expressed a panel of adipocyte-specific genes,
showed upregulation of insulin receptor and downregulation of
IGF1 receptor, secreted large amounts of adiponectin and showed
robust lipolysis in response to adrenergic stimulation. On the other
hand, we could not demonstrate insulin-stimulated glucose uptake
nor meaningful levels of leptin expression of secretion. The protocol
was successful when applied to a panel of cells harbouring
monogenic defects causing severe insulin resistance, some with
severe lipodystrophy, in humans. This simple protocol adds to the
repertoire of cell models available to interrogate the consequences
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of genes involved in human metabolic disease in the appropriate
genomic context and with endogenous expression levels. The
approach might be most suited to examination of disorders of lipid
droplet formation and function, of proximal insulin signalling, or,
for example, to assess naturally occurring ADIPOQ variants for
their impact on protein expression.
MATERIALS AND METHODS
Maintenance of dermal fibroblasts
All patient cell line studies were approved by the United Kingdom
National Health Service Research Ethics Committee. The probands and
families provided written informed consent, and studies were conducted
in accordance with the principles of the Declaration of Helsinki. Dermal
fibroblasts were cultured in Dulbecco’s modified Eagle medium
(DMEM; D6546, Sigma-Aldrich) supplemented with 10% foetal
bovine serum (HyClone), 2 mM L-glutamine (G7513, Sigma-Aldrich)
and 1% penicillin-streptomycin (P0781, Sigma-Aldrich) in a humidified
incubator (37°C, 5% CO2). Cells were passaged once a week at a 1:4 split
ratio.
Inducible lenti-PPARγ2 production and generation of stable cell
lines
The coding region of human PPARγ2 was amplified by PCR from a plasmid
containing PPARγ open reading frame (a gift from Erik Schoenmakers,
University of Cambridge) and cloned into pCR4TOPO vector (Zero Blunt
TOPO PCR Cloning Kit, Invitrogen). After sequencing confirmation, the
coding sequence was excised and inserted into the entry vector pEN-Tmcs
(ATCC MBA-251, LGC Standards) using SpeI and NotI restriction sites.
The expression cassette was then transferred to the pSLIK-Neo expression
lentivector (ATCC MBA-236, LGC Standards) using site-specific
recombination (Gateway LR Clonase II Enzyme Mix, Invitrogen). All
clones were confirmed by restriction digest screening and sequencing. To
produce recombinant lentivirus, 10 µg of pSLIK-PPARG plasmid together
with 7.5 µg of each of the two packaging plasmids, pMDLg/pRRE and
pRSVREV, and 5 µg of the plasmid coding for VSV-G envelope as well as
1 µg of pEGFP, were transfected into HEK293T cells on 10-cm culture
dishes using CalPhos Mammalian Transfection Kit (Clontech). The
transfection efficiency was monitored with GFP expression, revealed by
fluorescent microscopy. The medium was replaced after 12 h with
BioWhittaker Ultraculture Medium (Lonza) and 48 h post-transfection the
viral supernatants were harvested, filtered through a 0.45 µm filter and
concentrated by using Centricon Plus-70 Ultracel PL-100 (Millipore).
Dermal fibroblasts were trypsinised, seeded at ∼40% confluency and,
after adhering onto the culture plates (∼4 h after seeding), transduced with
the above concentrated lentiviral supernatant at low multiplicity of infection
in the presence of 8 µg/ml polybrene. Six-well plates were transduced with
8 µl lenti-PPARγ virus per well in 0.8 ml culture medium and, after adding
1.2 ml fresh medium per well 6-8 h later, cells were cultured for 2 days.
After removing the virus-containing medium, cells were then subjected to
G418 (Sigma-Aldrich) selection at a final concentration of 800 µg/ml for
10 days. Stable cell lines were maintained in culture medium containing
200 µg/ml G418. Inducibility of PPARγ overexpression with doxycycline
was assessed using western blotting.
Inducible lenti-C/EBPα production and generation of stable cell
lines
Human C/EBPα cDNA clone (TrueORF) was purchased from OriGene
Technologies (SC303472, Rockville, USA). The cDNA was released from
pCMV6-XL5 vector with EcoRI and XbaI restriction digestion, gel purified
and then inserted into pEN-Tmcs vector that had been digested with the
same restriction enzymes. After sequencing confirmation, the expression
cassette was then transferred to the pSLIK-Hygro expression lentivector
(ATCC MBA-236, LGC Standards) using site-specific recombination
(Gateway LR Clonase II Enzyme Mix, Invitrogen). Lenti-C/EBPα
production and generation of stable cell lines were carried out essentially
in the same way as described above except that selection of stable cell lines
was performed using hygromycin (200 mg/ml).
Adipogenic differentiation of stable cell lines
Stable dermal fibroblasts were treated with doxycycline (1 µg/ml) for 2 days
to induce PPARγ2 overexpression. Adipogenic differentiation was then
initiated by addition of adipogenic cocktail (1 µM insulin, 200 nM
rosiglitazone, 1 µM dexamethasone and 0.5 mM IBMX) for 2 days
followed by insulin and rosiglitazone for 2 days and then rosiglitazone
only for the rest of the culture. Doxycycline was included throughout the
reprogramming process in order to maintain PPARγ2 overexpression in
differentiating cells and the resulting mature adipocyte-like cells.
Generation of stem cell-derived adipocytes
The protocol used to generate adipocytes from stem cells has been adapted
from a previously published protocol (Ahfeldt et al., 2012). Briefly,
embryoid bodies (EBs) were derived from H9 embryonic stem cells.
Detached H9 colonies were then dissociated into clumps of 5-10 cells in EB
formation medium consisting of 15% KnockOut serum replacement
(Thermo Fisher Scientific) and 1% GlutaMAX (Thermo Fisher Scientific)
in DMEM (Sigma-Aldrich) supplemented with 4 μM Y-27632 (Sigma-
Aldrich). Cell clumps were then allowed to attach onto Ultralow attachment
plates (Corning). The medium was refreshed after 24 h. The EB medium
was replaced every other day for 5 days, after which the EBs were collected
into a pellet, resuspended in EB plating medium consisting of 10%
KnockOut Serum Replacement and 1% Glutamax in DMEM, and then
plated onto 0.1% gelatin-coated plates. Fresh EB plating medium was added
every other day until the EBs had attached and reached 90% confluency.
Cells were then passaged using 0.125% trypsin-EDTA (Sigma-Aldrich)
onto 0.1% gelatin-coated plates in adipocyte precursor (AP) medium
containing 15% KnockOut Serum Replacement and 1× GlutaMAX in
DMEM supplemented with 2.5 ng/ml bFGF (R&D Systems). The AP
medium was refreshed every other day.
AP cells were then plated onto each well of a 0.1% gelatin-coated six-well
plate in AP medium and transduced with lenti-PPARγ viruses in the
presence of 8 µg/ml polybrene. To induce adipocyte differentiation, the AP
medium was removed and adipocyte differentiation medium consisting of
15% KnockOut Serum Replacement (Lifetech), 0.5% non-essential amino
acids (Invitrogen), 1% Glutamax (Lifetech) in DMEM (Sigma-Aldrich)
supplemented with 1 μM dexamethasone (Sigma-Aldrich), 10 μg/ml
insulin (Actrapid, Novo Nordisk), 0.5 μM rosiglitazone (Sigma-Aldrich)
and 1 μg/ml doxycycline (Sigma-Aldrich) was applied to confluent
transduced AP cells. The adipocyte differentiation medium supplemented
with doxycyclinewas refreshed every other day for 16 or 21 days. Cells were
then maintained for a further 7 days in adipocyte differentiation medium
without doxycycline.
Sequencing
Sequencing reactions were performed with primers specific to respective
plasmids (Table S2) or PCR-amplified cDNA targets using BigDye
terminator (Invitrogen) according to the manufacturer’s protocol. PCR
products were treated with shrimp alkaline phosphatase (EF0511,
Fermentas) and ExoI (M0293L, BioLabs) to eliminate unincorporated
primers and dNTPs prior to sequencing reaction. Sequencing extension
products were purified using BigDye cleaning beads (BCB-100, MCLAB)
and then analysed with an ABI3730 DNA analyser. DNA sequence data
were analysed with Sequencher software (Gene Codes Corporation).
mRNA expression analysis
Total RNA samples were prepared using RNeasy Mini Kits (Qiagen) with a
DNase digestion step included to eliminate potential contaminating DNA
and quantified spectrophotometrically on a NanoDrop ND-1000 (Thermo
Fisher Scientific). First strand cDNA was reverse-transcribed from 400 ng
total RNA using an ImProm-II Reverse Transcription System (Promega)
with oligo(dT)15 as the primer, according to the manufacturer’s protocol.
Quantitative RT-PCR was carried out using an ABI PRISM 7900
Sequence Detection System (Applied Biosytems) with a SYBR Green PCR
Master Mix (Applied Biosystems) and gene-specific primers (Table S2).
Primers were custom-designed and synthesised by Sigma-Aldrich. cDNA
template (2 μl; diluted according to the relative expression level of each gene
of interest) was used in a 12 μl total reaction volume in each well in a 96-well
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reaction plate. For every gene analysed in the present study, we performed
dissociation curve analysis to ensure that the primers used did not form
primer dimers. The transcripts of each gene were amplified in duplicate.
Standard curves were constructed using serially diluted pooled cDNA
samples. The relative expression levels were calculated against each gene’s
standard curve with the Ct values of each gene with the housekeeping gene
HPRT1 as a loading control. Expression ofHPRT1 had equal levels between
control dermal fibroblasts and reprogrammed adipocyte-like cells
Protein expression analysis
Cells were washed with ice-cold PBS and harvested in M-PER Mammalian
Protein Extraction Reagent (Thermo Fisher Scientific), to which protease
inhibitor mini complete cocktail (Roche) was added at a 1:7 ratio. Proteins
were mixed with an equal volume of 2× SDS loading buffer and denatured at
100°C, and then resolved by SDS-PAGE and transferred to polyvinylidene
fluoride membranes using an iBlot system (Invitrogen). Blots were blocked
in TBST (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.1% Tween 20)
containing 5% milk or BSA (Sigma-Aldrich) and probed overnight at 4°C
with the following antibodies: anti-PPARγ (sc-7196, Santa Cruz
Biotechnology, 1:500 dilution), anti-adiponectin (ab13881, Abcam,
1:1000 dilution), anti-Glut4 (ab654, Abcam, 1:4000 dilution), anti-C/
EBPa (#2295, Cell Signaling Technology, 1:1000 dilution), anti-insulin
receptor β (sc-711, Santa Cruz Biotechnology, 1:500 dilution), anti-IGF1
receptor (sc-713, Santa Cruz Biotechnology, 1:500 dilution), anti-calnexin
(ab75801, Abcam, 1:10,000 dilution), anti-aP2 (sc-18661, Santa Cruz
Biotechnology, 1:5000 dilution), anti-lamin A/C (sc-20681, Santa Cruz
Biotechnology, 1:500 dilution), anti-perilipin (#3467s Cell Signaling
Technology, 1:1000 dilution) and anti-lamin R482W (SAB4200422,
Sigma-Aldrich, 1:5000 dilution). The bound primary antibodies were
detected by horseradish peroxidase-conjugated secondary antibodies
(1:5000 dilution), followed by ImmobilonTM Western chemiluminescent
HRP substrate (WBKLS0500, Millipore).
Glucose uptake assay
Adipocyte-like cells were serum starved in serum-free DMEM
containing 0.5% BSA for 2 h with change after 1 h. Cells were then
washed two times with HEPES glucose uptake buffer (120 mM NaCl,
5 mM KCl, 1.2 mM MgSO4, 10 mM NaHCO3, 1.3 mM CaCl2, 1.2 mM
KH2PO4 and 20 mM HEPES, pH 7.8) containing 0.5% BSA, and then
incubated in HEPES glucose uptake buffer containing 0.5% BSA in the
absence or presence of 100 nM insulin for 30 min at 37°C. Glucose
uptake was measured by incubating cells with 0.5 µCi/ml 2-deoxy-D-
[3H]glucose (Perkin-Elmer) for 5 min at 37°C. After three washes with
ice-cold PBS, cells were lysed with 0.5 M KOH for 30 min, and then
neutralised with 0.5 M HCl before scintillation counting. Protein
concentration in the cell lysate was determined using Coomassie Plus
Reagent (Thermo Fisher Scientific).
Lipolysis assay
Adipocyte-like cells were serum starved overnight (16 h) in serum-free
DMEM containing 0.5% BSA. Cells were washed with KRB-HEPES buffer
(118.5 mM NaCl, 4.75 mM KCl, 1.92 mM CaCl2, 1.19 mM KH2PO4,
1.19 mM MgSO4, 25 mM NaHCO3, 6 mM glucose and 10 mM HEPES,
pH 7.4) containing 4% fatty-acid-free BSA, and then incubated in KRB-
HEPES buffer with 4% fatty-acid-free BSA alone, with isoproterenol or
with IBMX at 37°C, 5% CO2 for 3 h. The culture medium was collected for
glycerol measurement using the free glycerol reagent (Sigma-Aldrich,
F6428).
Oil Red O staining
Cells were washed with PBS twice and fixed with 10% formalin solution
(Sigma-Aldrich, neutral buffered) at room temperature for 10 min. After
washing twice with PBS and twice with 60% isopropanol, cells were stained
with Oil Red O working solution [six parts stock Oil Red O (0.25% in
isopropanol): one part 60% isopropanol: three parts water] for 30 min.
Stained cells were washed with 60% isopropanol and kept in PBS for
scanning or microscopic imaging.
Immunofluorescence analysis
Cells on coverslips were fixed in 4% paraformaldehyde in PBS for 10 min
followed by one wash with TBS [50 mM Tris-HCl (pH 7.4), 150 mM
NaCl], permeabilisation in 0.2% Triton X-100 in PBS for 5 min, three
washes with TBS and quenching in fresh 0.1% sodium borohydride in TBS.
Coverslips were blocked with blocking buffer (10% horse serum, 1% BSA,
0.02% NaN3, 1× PBS) for 1 h, washed with TBS and incubated with anti-
ALMS1 (ab84892, Abcam, 1:1000 dilution) and anti-acetylated tubulin
(T7451, Sigma-Aldrich, 1:1000 dilution) in 1% BSA in TBS overnight at 4°
C. After washing, the cells were incubated with a 1:1000 dilution of Alexa
Fluor 488-conjugated goat anti-mouse IgG (A11001, Invitrogen) and Alexa
Fluor 555-conjugated goat anti-rabbit IgG (A21430, Invitrogen) for 45 min
at room temperature in the dark, washed with TBS, mounted on glass slides
using the ProLong Gold Antifade Reagent with DAPI (P36931, Invitrogen)
and inspected with a Zeiss LSM510 Meta confocal laser scanning
microscope.
Statistical analysis
Data are expressed as mean±s.e.m. from at least three independent
experiments (n≥3). Statistical analyses were performed in GraphPad Prism
5.0 (GraphPad Software, San Diego, CA, USA). Statistical significance was
determined by pairwise comparisons using a two-tailed unpaired Student’s
t-test, with P<0.05 considered significant. The investigators were not blinded
to the group allocation during the experiments.
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